Click here to take the CME Evaluation and Post-Meeting Survey
Dr. W. David Hardy is a scientific and medical consultant focusing on developing novel vaccine and cure/remission strategies for human viral diseases. He serves as Adjunct Clinical Professor of Medicine at the Keck School of Medicine of USC. He served as Senior Director of Research at Whitman-Walker Health (Washington, DC) overseeing NIH-funded ACTG trials and HIV Cohort studies and industry-sponsored trials from 2015-2018. While there he held an academic appointment as Adjunct Professor of Medicine at Johns Hopkins University School of Medicine, Baltimore, Maryland. From 2002 to 2013 he served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. Dr. Hardy also served as chief medical officer for Calimmune (2013-2015), a small California-based biotechnology company, funded by the California Institute for Regenerative Medicine (CIRM), using gene-modified CD4+ T cells and hematopoietic stem cells as a potential cure for HIV infection.
He received his medical degree from Baylor College of Medicine, Houston, TX and completed his residency in internal medicine at Harbor-UCLA Medical Center in Torrance, California. Early in the AIDS epidemic, he completed a clinical fellowship in infectious diseases/immunology and clinical research at the UCLA School of Medicine under the direction of Dr. Michael Gottlieb, the physician who recognized and reported the first cases of AIDS. He also completed a laboratory fellowship in molecular retrovirology with Irvin Chen, PhD at the David Geffen School of Medicine at UCLA focusing on development of retroviral vector delivery of gene therapy and vaccine applications.
Dr. Hardy has cared for persons with HIV infection since 1982 and conducted research on HIV and related diseases since 1984. His research has focused on treatment and prevention of opportunistic infections, antiretroviral therapy, immunotherapies, hepatitis treatments as well as retroviral vector research, cellular and gene therapy as strategies for cure of HIV infection. Dr Hardy served as Chair of the Board of Directors of the HIV Medicine Association (HIVMA) 2018-2019. Currently, he serves as Chair of the Education Committee and member of the Executive Committee of the American Academy of HIV Medicine (AAHIVM). He has served as editor-in-chief of AAHIVM’s comprehensive clinical textbook, Fundamentals of HIV Medicine for the HIV Specialist published in 2007, 2008, 2012, 2017, 2019 and 2021. He has volunteered with several community-based organizations, including AIDS Research Alliance, the Alliance for Housing and Healing, Being Alive-Empowering People with HIV/AIDS, Project Angel Food, AIDS Project-Los Angeles and the Foundation for the AIDS Monument.
At the completion of this educational session, learners will:
1. Be able to discuss new clinically relevant advances in antiretroviral therapy and prevention strategies for HIV.
2. Learn about new drugs for HIV treatment and prevention.
3. Recognize emerging adverse effects including metabolic effects associated with antiretrovirals used for treatment and prevention of HIV.
This CME activity has approved for AMA PRA Category 1 Credit™
for August 17, 2022, as a live activity. This activity will also be available as an enduring activity from August 18, 2022, through August 16, 2025.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. W. David Hardy (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Advisory Board Member to: Gilead, Merck, and GSK/ViiV; Consultant to: Enochian Biosciences. Dr. Hardy submitted their slides in advance for adequate peer review and will support their presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare